Navigation Links
A New Option for Patients Suffering From QT Syndrome

Long QT syndrome is a disorder of the heart’s electrical system, which can be inherited or acquired. The syndrome’s name comes from // an elongated QT interval on an electrocardiogram. People with LQTS are prone to develop an extremely rapid heart rhythm, often brought on by exercise, emotion or loud noise. This improper rhythm interferes with blood flow to the brain and can result in fainting or cardiac arrest. A new study shows a specific surgery can reduce the risk of fainting or sudden death in people with a disorder called long QT syndrome.

Beta-blockers can also slow the heartbeat and prevent arrhythmias in LQTS patients. However, about a fourth of patients continue to experience symptoms while on the medication.

One current treatment method involves an implanted defibrillator that automatically delivers a shock to the heart with an irregular rhythm to return the rhythm to normal. Though researchers say this is the best protection, some patients experience storms of cardiac arrest resulting in multiple shocks. This can be frightening and interfere with quality of life.

The new alternative is a 40-minute surgery called left cardiac sympathetic denervation. The procedure reduces the heart’s control from the sympathetic nervous system by removing part of the nerves leading to the heart. The sympathetic nervous system is responsible for involuntary biological functions such as breathing and heart rate.

Based of the study results,of 147 patients, researchers found surgery reduced fainting and cardiac arrest by 91 percent, even in a population of patients at an especially high risk.
'"/>




Page: 1

Related medicine news :

1. Surprising Cystic Fibrosis Finding That Could Be A Helpful Treatment Option
2. New Treatment Option for Colorectal Cancer
3. Aspirin Not The Ideal Treatment Option For Stroke Patients
4. Better Treatment Options For Osteoporosis
5. New Treatment Option For Menstrual Migraine
6. The Options For Relieving Chest Pain In the Elderly Questioned
7. Treatment Options For Retinitis Pigmentosa Questioned
8. Another Treatment Option for Benign Tumors
9. The Latest Preventative Treatment Option for Prostate Cancer
10. Yet Another Treatment Option For Cancer
11. Acupuncture An Effective Treatment Option For Arthritis

Post Your Comments:
(Date:11/27/2009)...UILLY-SUR-SEINE,France,Nov.27/PRNewswire/--TeamGar...teamdedicatedtoethicalsportinganddevelopingthenext...illbecomeTeamGarmin-TransitionswiththeadditionofTr...Opticalistheworld,sleadingmanufacturerofadaptiveey...yinthewidestselectionofspectaclelensessuchasTransi...
(Date:11/27/2009)... XenaCare Holdings has announced th...is Foundation, one of the largest nonprofit organi... health education. , Delr... Holdings, Inc. (OTCBB: XCHO), a company specializ...nsumer healthcare products, has announced today th...
(Date:11/27/2009)...tes to bring unprecedented medical, economic burde...HealthDay News) -- The number of people with diabe...r the next 25 years, a new study predicts. , Th...lion people with the disease, up from 23.7 million...ng people with diabetes will triple, the study als...
(Date:11/27/2009)... Voyant Health™ announced tod...as licensed its TraumaCad Enterprise orthopedic te...w solution. , (PRWEB) Nov...oday that Spectrum Health (Grand Rapids, Michigan)...templating solution and its TraumaCad Extend workf...
(Date:11/27/2009)... Specialist manufacturers who use m...re saving millions of dollars by bringing in techn... Increasing numbers of pro-active medical manufact...the concept stage of their projects, ensuring that...gn processes or potentially outdated technology. ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...LLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RES...ve merger,agreement pursuant to which Royal Philip... commence a tender offer to acquire all of the out... a,premium of approximately 31% over Respironics, ...
... study finds that most general surgeons do not dis...breast cancer treatment. The analysis shows that o...or breast conserving surgery have such discussions...nstruction has increased treatment choices for wom...
...Calif., Dec. 20 ISTA Pharmaceuticals,Inc. (Nasdaq...ed a New Drug,Application (NDA) to the U.S. Food a...ce-daily). The Company is seeking approval for Xib...opical non-steroidal anti-inflammatory compound fo...
...om Community Will Fund 20 Percent of Cost for New ...undation announced that it has reached its $50 mil...mportant philanthropic effort Sharp has ever,under...com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
...ON, Dec. 20 Today URAC called for,comments on maj...alth Web,Site, HIPAA Privacy (Business Associate a...sociate and Covered Entity) accreditation programs...ne for public comment is Feb. 10, 2008., (LOGO: ...
...N, Va., Dec. 20 MCG Capital,Corporation (Nasdaq: ...ferred,equity investment to support the acquisitio...ld & Lamb is a medical-financial services company ...tion industry,since 2001. Having completed in exce...
Other Medicine News:Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Reconstruction surgery rarely discussed with breast cancer patients 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2
(Date:11/25/2009)...wire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amed...imallydisruptivesurgicaltreatmentsforthespine,anno...vember30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferenc...ntfortheCompany,sproductsandwillincludecommentsfro...n.Thedial-innumbersare1-877-407-4018fordomesticcal...
(Date:11/25/2009)...dJOHANNESBURG,November25/PRNewswire/--,iThembaPhar...cedtoday,thattheyhavesignedacollaborativeagreement...is,sworldclasscomputationalchemistryandleaddiscove...iontoprovidemedicinaland,syntheticchemistrysupport...entnetwork.iThembaPharmaceuticalsandPyxisDiscovery...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Approves NovoLog 28R 29 Labeling Update 51814 1FDA Approves NovoLog 28R 29 Labeling Update 51814 2FDA Approves NovoLog 28R 29 Labeling Update 51814 3FDA Approves NovoLog 28R 29 Labeling Update 51814 4U S Students Academic Interests Tend to Wane in Middle School 51812 1U S Students Academic Interests Tend to Wane in Middle School 51812 2Michael Steele Chairman of the Republican National Committee Will Hold a Press Conference on Health Care the Republican Alternative at 9 am on Mon 51810 1
...at data,presented recently at the 17th Annual Meet...iology demonstrate that the Genous Bio-engineered ...eluting stents., Presented by Federico Piscione, ...fessor with the Federico II University of Naples,s...dicine and Cardiovascular,Sciences, the data were ...
...ion Application currently u...erapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTA) today...domized phase III trial comparing OPAXIO(TM) (pacl...orelbine for the treatment of PS 2,(performance st...ll cell,lung cancer (NSCLC) in the Journal of Thor...
Other Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
...ested Timeter® Classic Flowmeters demonstrates...oviders and patients alike. You can see it in the ... can see it in the performance, year after year. E...d and engineered to the highest standards of perfo...
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/Y Bar & 2 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar
Soft-Touch Timeter® 8 LPM Flowmeter
Medicine Products: